Amedisys Capital Surpluse from 2010 to 2025

AMED Stock  USD 92.36  0.05  0.05%   
Amedisys' Capital Surpluse is increasing over the years with slightly volatile fluctuation. Capital Surpluse is expected to dwindle to about 600.6 M. During the period from 2010 to 2025 Amedisys Capital Surpluse annual values regression line had geometric mean of  575,568,063 and mean square error of 3927.8 T. View All Fundamentals
 
Capital Surpluse  
First Reported
2009-06-30
Previous Quarter
758.7 M
Current Value
768.8 M
Quarterly Volatility
123.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amedisys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amedisys' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.6 M, Interest Expense of 37.8 M or Selling General Administrative of 333.3 M, as well as many indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 3.0E-4 or PTB Ratio of 2.57. Amedisys financial statements analysis is a perfect complement when working with Amedisys Valuation or Volatility modules.
  
Check out the analysis of Amedisys Correlation against competitors.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Latest Amedisys' Capital Surpluse Growth Pattern

Below is the plot of the Capital Surpluse of Amedisys over the last few years. It is Amedisys' Capital Surpluse historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amedisys' overall financial position and show how it may be relating to other accounts over time.
Capital Surpluse10 Years Trend
Slightly volatile
   Capital Surpluse   
       Timeline  

Amedisys Capital Surpluse Regression Statistics

Arithmetic Mean591,341,748
Geometric Mean575,568,063
Coefficient Of Variation23.86
Mean Deviation115,460,998
Median600,646,515
Standard Deviation141,116,786
Sample Variance19913.9T
Range504.7M
R-Value0.90
Mean Square Error3927.8T
R-Squared0.82
Slope26,773,563
Total Sum of Squares298709.2T

Amedisys Capital Surpluse History

2025600.6 M
2024868.3 M
2022755.1 M
2021728.1 M
2020698.3 M
2019645.3 M
2018603.7 M

About Amedisys Financial Statements

Amedisys stakeholders use historical fundamental indicators, such as Amedisys' Capital Surpluse, to determine how well the company is positioned to perform in the future. Although Amedisys investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amedisys' assets and liabilities are reflected in the revenues and expenses on Amedisys' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amedisys. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Surpluse868.3 M600.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out the analysis of Amedisys Correlation against competitors.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.35)
Earnings Share
2.52
Revenue Per Share
71.004
Quarterly Revenue Growth
0.057
Return On Assets
0.0627
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.